Published in Cancer Weekly, March 28th, 2000
"The significance of CD4+ lymphocytes and major histocompatibility complex (MHC) class II-restricted antigens in antitumor immunity has been demonstrated in several animal models as well as in some human tumors," wrote A. Ladanyi and colleagues, U.S. National Cancer Institute, Maryland, USA. "However, because of the lack of known class II-restricted antigens, the participation of CD4+ cells in antitumor responses has not been well characterized."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.